Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course

Cavagna, Lorenzo ; Trallero-Araguás, Ernesto ; Meloni, Federica ; Cavazzana, Ilaria ; Rojas-Serrano, Jorge ; Feist, Eugen ; Zanframundo, Giovanni ; Morandi, Valentina ; Meyer, Alain and Pereira da Silva, Jose Antonio , et al. (2019) In Journal of Clinical Medicine 8(11).
Abstract

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome)... (More)

Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Clinical Medicine
volume
8
issue
11
article number
2013
publisher
MDPI AG
external identifiers
  • scopus:85081624440
  • pmid:31752231
ISSN
2077-0383
DOI
10.3390/jcm8112013
language
English
LU publication?
no
id
85c774f0-63e4-479a-86d7-7271d580a706
date added to LUP
2020-12-18 15:27:49
date last changed
2024-07-12 06:35:36
@article{85c774f0-63e4-479a-86d7-7271d580a706,
  abstract     = {{<p>Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group's cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The "ex-novo" occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies' positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.</p>}},
  author       = {{Cavagna, Lorenzo and Trallero-Araguás, Ernesto and Meloni, Federica and Cavazzana, Ilaria and Rojas-Serrano, Jorge and Feist, Eugen and Zanframundo, Giovanni and Morandi, Valentina and Meyer, Alain and Pereira da Silva, Jose Antonio and Matos Costa, Carlo Jorge and Molberg, Oyvind and Andersson, Helena and Codullo, Veronica and Mosca, Marta and Barsotti, Simone and Neri, Rossella and Scirè, Carlo and Govoni, Marcello and Furini, Federica and Lopez-Longo, Francisco Javier and Martinez-Barrio, Julia and Schneider, Udo and Lorenz, Hanns-Martin and Doria, Andrea and Ghirardello, Anna and Ortego-Centeno, Norberto and Confalonieri, Marco and Tomietto, Paola and Pipitone, Nicolò and Rodriguez Cambron, Ana Belen and Blázquez Cañamero, María Ángeles and Voll, Reinhard Edmund and Wendel, Sarah and Scarpato, Salvatore and Maurier, Francois and Limonta, Massimiliano and Colombelli, Paolo and Giannini, Margherita and Geny, Bernard and Arrigoni, Eugenio and Bravi, Elena and Migliorini, Paola and Mathieu, Alessandro and Piga, Matteo and Drott, Ulrich and Delbrueck, Christiane and Bauhammer, Jutta and Cagnotto, Giovanni and Vancheri, Carlo and Sambataro, Gianluca and De Langhe, Ellen and Sainaghi, Pier Paolo and Monti, Cristina and Gigli Berzolari, Francesca and Romano, Mariaeva and Bonella, Francesco and Specker, Christof and Schwarting, Andreas and Villa Blanco, Ignacio and Selmi, Carlo and Ceribelli, Angela and Nuno, Laura and Mera-Varela, Antonio and Perez Gomez, Nair and Fusaro, Enrico and Parisi, Simone and Sinigaglia, Luigi and Del Papa, Nicoletta and Benucci, Maurizio and Cimmino, Marco Amedeo and Riccieri, Valeria and Conti, Fabrizio and Sebastiani, Gian Domenico and Iuliano, Annamaria and Emmi, Giacomo and Cammelli, Daniele and Sebastiani, Marco and Manfredi, Andreina and Bachiller-Corral, Javier and Sifuentes Giraldo, Walter Alberto and Paolazzi, Giuseppe and Saketkoo, Lesley Ann and Giorgi, Roberto and Salaffi, Fausto and Cifrian, Jose and Caporali, Roberto and Locatelli, Francesco and Marchioni, Enrico and Pesci, Alberto and Dei, Giulia and Pozzi, Maria Rosa and Claudia, Lomater and Distler, Jorg and Knitza, Johannes and Schett, George and Iannone, Florenzo and Fornaro, Marco and Franceschini, Franco and Quartuccio, Luca and Gerli, Roberto and Bartoloni, Elena and Bellando Randone, Silvia and Zampogna, Giuseppe and Gonzalez Perez, Montserrat I and Mejia, Mayra and Vicente, Esther and Triantafyllias, Konstantinos and Lopez-Mejias, Raquel and Matucci-Cerinic, Marco and Selva-O'Callaghan, Albert and Castañeda, Santos and Montecucco, Carlomaurizio and Gonzalez-Gay, Miguel Angel}},
  issn         = {{2077-0383}},
  language     = {{eng}},
  month        = {{11}},
  number       = {{11}},
  publisher    = {{MDPI AG}},
  series       = {{Journal of Clinical Medicine}},
  title        = {{Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course}},
  url          = {{http://dx.doi.org/10.3390/jcm8112013}},
  doi          = {{10.3390/jcm8112013}},
  volume       = {{8}},
  year         = {{2019}},
}